Roughly 15.5 million U.S. adults now live with a current ADHD diagnosis, about 6% of the adult population, and more than half of them were diagnosed after age 18. Yet stimulant shortages, side effect concerns, and personal preference mean stimulants aren’t always the right fit. In fact, over 70% of adults prescribed stimulant ADHD medication have reported trouble filling their prescriptions in recent years. That’s where non-stimulant ADHD medications come in.
If you’ve been told stimulants aren’t for you, or you simply want to understand every option before committing to a treatment plan, this guide walks through the FDA-approved and commonly used non-stimulant ADHD medications available today. At TTT.coach, we believe medication decisions should never happen in isolation. They work best as one piece of a whole-person plan that also considers sleep, mood, anxiety, and daily habits. Think. Transform. Thrive.
Why Consider a Non-Stimulant?
Stimulants remain first-line ADHD treatment because they tend to work faster and produce larger symptom improvements. But non-stimulant ADHD medications are a genuinely effective alternative for people who:
- Don’t respond fully to stimulants, or experience intolerable side effects (reported in up to 30 to 50% of patients)
- Have a history of substance use, where avoiding controlled substances is a priority
- Experience anxiety that stimulants can worsen
- Need coverage that doesn’t rise and fall with each dose
- Are affected by ongoing stimulant supply shortages
- Simply prefer not to take a controlled substance
None of the medications below carry abuse potential, which also means simpler refills and fewer prescribing restrictions, particularly helpful for telehealth patients.
The Main Non-Stimulant ADHD Medications
Four non-stimulant options currently carry FDA approval for ADHD: atomoxetine, viloxazine, guanfacine extended-release, and clonidine extended-release. A few additional medications are used off-label. Here’s how they differ.
1. Atomoxetine (Strattera)
The first non-stimulant approved for ADHD, back in 2003, and still the most-studied option. Atomoxetine is a norepinephrine reuptake inhibitor, meaning it increases norepinephrine availability in brain regions tied to attention and impulse control. It typically takes 4 to 8 weeks to reach full effect, and among non-stimulant ADHD medications it generally has the strongest evidence base for adults, especially for inattentive-type symptoms.
2. Viloxazine (Qelbree)
Approved for children in 2021 and extended to adults in 2022, viloxazine works through a similar norepinephrine-based mechanism as atomoxetine but may begin producing effects sooner, often within 2 to 4 weeks. It’s taken once daily, and the capsule can be opened and sprinkled on food, which some patients find easier to manage. The tradeoff: no generic is available yet, so it tends to cost more out of pocket.
3. Guanfacine Extended-Release (Intuniv)
An alpha-2A adrenergic agonist originally developed as a blood pressure medication. Guanfacine ER is FDA-approved for children and adolescents (adult use is off-label) and tends to be especially helpful for hyperactivity, impulsivity, and emotional reactivity, sometimes called the “ADHD-plus-anger” presentation. It’s often combined with a stimulant rather than used alone.
4. Clonidine Extended-Release (Kapvay)
Also an alpha-2 agonist, clonidine ER works similarly to guanfacine but tends to be more sedating, which can be an advantage for patients whose ADHD symptoms disrupt sleep. Blood pressure monitoring is recommended, since both clonidine and guanfacine can lower it.
5. Off-Label Options: Bupropion and Venlafaxine
Bupropion (Wellbutrin) is frequently used off-label when ADHD and depression overlap, since it addresses both. Venlafaxine (Effexor), an SNRI, is sometimes used off-label as well, though evidence is more limited. These require a careful, individualized conversation with your prescriber.
How to Choose the Right Option
There’s no single “best” non-stimulant ADHD medication. The right choice depends on your specific symptom pattern and co-occurring conditions:
- Inattention-dominant ADHD: Atomoxetine or viloxazine are typically tried first
- Hyperactivity, impulsivity, or emotional reactivity: Guanfacine or clonidine ER often perform better
- ADHD with anxiety: Non-stimulants are frequently preferred, since they don’t carry the activating effect that can worsen anxiety symptoms
- ADHD with depression: Bupropion may address both conditions at once
- ADHD with a history of substance use: Non-stimulants are strongly preferred over controlled substances
This is exactly the kind of nuanced decision that benefits from whole-person psychiatric care rather than a one-size-fits-all prescription. A thorough evaluation, looking at your full mental health picture and not just an ADHD symptom checklist, is what actually determines which medication fits.
What to Expect: Timeline and Side Effects
Unlike stimulants, which can work within hours, non-stimulant ADHD medications build gradually. Most require 4 to 8 weeks at a therapeutic dose before you can fairly judge whether they’re working. Common side effects vary by medication:
- Atomoxetine and viloxazine: Can raise heart rate and blood pressure; possible nausea, fatigue, or decreased appetite
- Guanfacine and clonidine: Can lower blood pressure; possible drowsiness, especially early in treatment
- All carry an FDA black-box warning regarding suicidal thinking in children and adolescents, which underscores the importance of close monitoring, particularly in the first few months
Keeping a simple daily log of focus, mood, sleep, and any side effects during the first month gives your prescriber real data to work with, far more useful than relying on memory at a follow-up appointment.
The TTT.coach Approach: Treating the Whole Person
Medication addresses the neurological side of ADHD, but it’s rarely the whole story. Many patients we see also carry unaddressed anxiety, mood symptoms, or sleep disruption that shape how well any ADHD treatment works. That’s why our model pairs medication management with attention to the full picture, because a prescription without context isn’t complete care.
If you’re exploring ADHD treatment, we also cover related concerns that often overlap: anxiety, depression, OCD, sleep disorders, and mood disorders. Our telehealth psychiatric services are available nationwide, so you can access transparent, evidence-based care from wherever you are.
Frequently Asked Questions
Are non-stimulant ADHD medications as effective as stimulants?
Generally, no. Stimulants tend to produce larger symptom improvements and work faster. But non-stimulants are genuinely effective for many people, particularly when stimulants aren’t tolerated or appropriate, and they remain a solid evidence-based option.
How long do non-stimulant ADHD medications take to work?
Most take 2 to 8 weeks to reach full effect, depending on the medication. Viloxazine may show early benefits within 2 to 4 weeks, while atomoxetine typically takes 4 to 8 weeks.
Can I combine a non-stimulant with a stimulant?
Yes. Guanfacine and clonidine ER are frequently added to stimulant treatment to address symptoms like emotional reactivity or sleep issues that the stimulant alone doesn’t cover. This should always be managed by your prescriber.
Are non-stimulant ADHD medications safe for people with anxiety?
They’re often preferred for ADHD with co-occurring anxiety, since they don’t carry the same activating quality stimulants can have. Still, individual response varies, so monitoring matters.
Do non-stimulant ADHD medications have withdrawal effects?
Atomoxetine has no documented discontinuation syndrome and doesn’t require tapering. Guanfacine and clonidine, however, should generally be tapered under medical supervision, since stopping abruptly can cause blood pressure rebound.
Is it normal to try more than one non-stimulant before finding the right fit?
Yes, it’s common. Response varies significantly between individuals, and finding the right medication, or combination, often takes some trial and adjustment guided by your prescriber.
Take the Next Step
Non-stimulant ADHD medications open up real options for people who want effective treatment without a controlled substance, or who need a different approach after stimulants haven’t worked. But the right choice depends on your full picture, not just a diagnosis code. TTT.coach offers nationwide telehealth psychiatric care built around treating the whole person, not just the symptom. Ready to find the plan that actually fits you? Visit ttt.coach or call +1 (520) 689-6814 to schedule an evaluation.
References
- Centers for Disease Control and Prevention. (2025). Data on ADHD in Children. https://www.cdc.gov/adhd/data/index.html
- Centers for Disease Control and Prevention, National Center for Health Statistics. (2025). ADHD Prevalence and Health Care Access Among Adults, 2024: Data Brief No. 543. https://www.cdc.gov/nchs/products/databriefs/db543.htm
- National Institute of Mental Health. Attention-Deficit/Hyperactivity Disorder (ADHD). https://www.nimh.nih.gov/health/topics/attention-deficit-hyperactivity-disorder-adhd
- Wolraich, M.L., et al. (2019). Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. Pediatrics, American Academy of Pediatrics. https://publications.aap.org/pediatrics/article/144/4/e20192528/81590
- Children and Adults with Attention-Deficit/Hyperactivity Disorder (CHADD). (2026). General Prevalence of ADHD in Adults. https://chadd.org/about-adhd/general-prevalence-adults/
- PubMed / National Library of Medicine. Nonstimulant Medications for Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. https://pubmed.ncbi.nlm.nih.gov/39760346/
- U.S. Food and Drug Administration. Qelbree (viloxazine extended-release) Prescribing Information. https://www.accessdata.fda.gov/scripts/cder/daf/
- U.S. Food and Drug Administration. Intuniv (guanfacine extended-release) Prescribing Information. https://www.accessdata.fda.gov/scripts/cder/daf/
- Substance Abuse and Mental Health Services Administration (SAMHSA). Attention-Deficit/Hyperactivity Disorder. https://www.samhsa.gov/mental-health/adhd
- American Psychiatric Association. What Is ADHD? https://www.psychiatry.org/patients-families/adhd/what-is-adhd
Disclaimer: This article is for informational and educational purposes only and does not constitute medical advice. It does not create a patient-provider relationship with TTT.coach or any of its clinicians. If you are experiencing a mental health crisis, call or text 988 to reach the Suicide & Crisis Lifeline, available 24/7. For questions about TTT.coach psychiatric services, visit https://ttt.coach or call +1 (520) 689-6814.